A detailed history of Keybank National Association transactions in Moderna, Inc. stock. As of the latest transaction made, Keybank National Association holds 3,928 shares of MRNA stock, worth $236,465. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,928
Previous 3,534 11.15%
Holding current value
$236,465
Previous $376,000 23.94%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 31, 2024

BUY
$101.21 - $166.61 $39,876 - $65,644
394 Added 11.15%
3,928 $466,000
Q1 2024

May 14, 2024

BUY
$85.37 - $115.44 $301,697 - $407,964
3,534 New
3,534 $376,000
Q3 2023

Nov 08, 2023

SELL
$96.41 - $126.61 $3,759 - $4,937
-39 Reduced 1.21%
3,176 $328,000
Q2 2023

Aug 01, 2023

BUY
$118.5 - $160.53 $31,521 - $42,700
266 Added 9.02%
3,215 $390,000
Q1 2023

May 10, 2023

SELL
$135.66 - $197.02 $37,577 - $54,574
-277 Reduced 8.59%
2,949 $452,000
Q4 2022

Jan 31, 2023

BUY
$118.38 - $210.04 $23,439 - $41,587
198 Added 6.54%
3,226 $579,000
Q3 2022

Oct 27, 2022

SELL
$118.07 - $194.18 $23,023 - $37,865
-195 Reduced 6.05%
3,028 $358,000
Q2 2022

Aug 08, 2022

BUY
$117.13 - $176.59 $40,526 - $61,100
346 Added 12.03%
3,223 $460,000
Q1 2022

Apr 28, 2022

BUY
$126.46 - $235.05 $65,885 - $122,461
521 Added 22.11%
2,877 $496,000
Q4 2021

Feb 07, 2022

SELL
$225.82 - $368.51 $219,722 - $358,560
-973 Reduced 29.23%
2,356 $598,000
Q3 2021

Nov 08, 2021

BUY
$221.9 - $484.47 $252,744 - $551,811
1,139 Added 52.01%
3,329 $1.28 Million
Q2 2021

Aug 12, 2021

SELL
$129.91 - $234.98 $103,928 - $187,984
-800 Reduced 26.76%
2,190 $515,000
Q1 2021

May 07, 2021

BUY
$109.18 - $185.98 $96,842 - $164,964
887 Added 42.18%
2,990 $392,000
Q4 2020

Feb 09, 2021

BUY
$65.74 - $169.86 $138,251 - $357,215
2,103 New
2,103 $220,000

Others Institutions Holding MRNA

About Moderna, Inc.


  • Ticker MRNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 391,200,000
  • Market Cap $23.6B
  • Description
  • Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, resp...
More about MRNA
Track This Portfolio

Track Keybank National Association Portfolio

Follow Keybank National Association and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Keybank National Association, based on Form 13F filings with the SEC.

News

Stay updated on Keybank National Association with notifications on news.